Researcher.Life Logo

BioDrugs : Impact Factor & More

eISSN: 1179-190XpISSN: 1173-8804

Aims and Scope of BioDrugs

BioDrugs is a peer-reviewed pharmacology journal. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. It has a 2020 impact factor of 5.807. It is published by Adis International (SpringerNature). Less

Key Metrics

CiteScore
10.5
Eigenfactor
0.001 - 0.005
H-Index
76
Impact Factor
5 - 10
SJR
Q1Pharmacology
SNIP
1.74
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on BioDrugs

BioDrugs Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher ADIS INT LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1994
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in BioDrugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BioDrugs

Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes.
  • 22 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Interleukin-23 Inhibitors in Inflammatory Bowel Disease.
  • 21 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy.
  • 13 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.
  • 13 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis.
  • 3 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities.
  • 30 Mar 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes.
  • 22 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Interleukin-23 Inhibitors in Inflammatory Bowel Disease.
  • 21 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy.
  • 13 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.
  • 13 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis.
  • 3 Apr 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities.
  • 30 Mar 2026
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

FAQs on BioDrugs